Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

G. Hanna · SciRah

Researcher profile · Semantic Scholar

G. Hanna

Share profile

G. Hanna — researcher profile on SciRah

h-index: 36
Works: 92
Citations: 4,699

Most-cited papers

Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy
S. Palmer, F. Maldarelli, A. Wiegand, B. Bernstein +6 more
2008Proceedings of the National Academy of Sciences of the United States of America673 citations Open access
Semantic Scholar
ART Suppresses Plasma HIV-1 RNA to a Stable Set Point Predicted by Pretherapy Viremia
F. Maldarelli, S. Palmer, M. King, A. Wiegand +14 more
2007PLoS Pathogens344 citations Open access
Semantic Scholar
Genotypic Correlates of Phenotypic Resistance to Efavirenz in Virus Isolates from Patients Failing Nonnucleoside Reverse Transcriptase Inhibitor Therapy
L. Bacheler, S. Jeffrey, G. Hanna, R. D'Aquila +11 more
2001Journal of Virology251 citations Open access
Semantic Scholar
Antiretroviral resistance during successful therapy of HIV type 1 infection.
J. Martinez-Picado, M. D. de Pasquale, N. Kartsonis, G. Hanna +12 more
2000Proceedings of the National Academy of Sciences of the United States of America230 citations Open access
Semantic Scholar
Recommendations for Analytical Antiretroviral Treatment Interruptions in HIV Research Trials – Report of a Consensus Meeting
B. Julg, L. Dee, J. Ananworanich, D. Barouch +45 more
2019The Lancet HIV176 citations Open access
Semantic Scholar
Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus–1 Infection: Week 48 Results of the DRIVE-AHEAD Trial
C. Orkin, K. Squires, J. Molina, P. Sax +13 more
2018Clinical Infectious Diseases162 citations Open access
Semantic Scholar
The Tablet Formulation of Lopinavir/Ritonavir Provides Similar Bioavailability to the Soft-Gelatin Capsule Formulation With Less Pharmacokinetic Variability and Diminished Food Effect
C. Klein, Y. Chiu, W. Awni, T. Zhu +6 more
2007Journal of Acquired Immune Deficiency Syndromes161 citations Open access
Semantic Scholar
“White Coat Compliance” Limits the Reliability of Therapeutic Drug Monitoring in HIV-1—Infected Patients
T. Podsadecki, B. Vrijens, E. Tousset, R. Rode +1 more
2008HIV Clinical Trials148 citations Open access
Semantic Scholar
In Vitro Antiviral Characteristics of HIV-1 Attachment Inhibitor BMS-626529, the Active Component of the Prodrug BMS-663068
B. Nowicka-Sans, Yi-Fei Gong, Brian Mcauliffe, I. Dicker +17 more
2012Antimicrobial Agents and Chemotherapy137 citations Open access
Semantic Scholar
Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial.
J. Molina, K. Squires, P. Sax, P. Cahn +134 more
2018The Lancet HIV136 citations
Semantic Scholar
A Once-Daily Lopinavir/Ritonavir-Based Regimen Provides Noninferior Antiviral Activity Compared With a Twice-Daily Regimen
Margaret A. Johnson, J. Gathe, D. Podzamczer, J. Molina +6 more
2006Journal of Acquired Immune Deficiency Syndromes132 citations Open access
Semantic Scholar
Patterns of resistance mutations selected by treatment of human immunodeficiency virus type 1 infection with zidovudine, didanosine, and nevirapine.
G. Hanna, Victoria A. Johnson, D. Kuritzkes, D. Richman +4 more
2000Journal of Infectious Diseases125 citations
Semantic Scholar
A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy.
D. W. Cameron, B. D. da Silva, J. Arribas, R. Myers +6 more
2008Journal of Infectious Diseases121 citations Open access
Semantic Scholar
Clinical use of genotypic and phenotypic drug resistance testing to monitor antiretroviral chemotherapy.
G. Hanna, R. D'Aquila
2001Clinical Infectious Diseases121 citations
Semantic Scholar
Pharmacodynamics, safety, and pharmacokinetics of BMS-663068, an oral HIV-1 attachment inhibitor in HIV-1-infected subjects.
R. Nettles, D. Schürmann, Li Zhu, M. Stonier +9 more
2012Journal of Infectious Diseases98 citations Open access
Semantic Scholar
Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial
Margaret A. Johnson, Princy N. Kumar, J. Molina, G. Rizzardini +10 more
2019Journal of Acquired Immune Deficiency Syndromes90 citations Open access
Semantic Scholar
Decreased adherence to antiretroviral therapy observed prior to transient human immunodeficiency virus type 1 viremia.
T. Podsadecki, B. Vrijens, E. Tousset, R. Rode +1 more
2007Journal of Infectious Diseases87 citations Open access
Semantic Scholar
Activity of the HIV-1 Attachment Inhibitor BMS-626529, the Active Component of the Prodrug BMS-663068, against CD4-Independent Viruses and HIV-1 Envelopes Resistant to Other Entry Inhibitors
Zhu-Fang Li, N. Zhou, Yongnian Sun, N. Ray +3 more
2013Antimicrobial Agents and Chemotherapy76 citations Open access
Semantic Scholar
A Lopinavir/Ritonavir-Based Once-Daily Regimen Results in Better Compliance and Is Non-inferior to a Twice-Daily Regimen Through 96 Weeks
J. Molina, T. Podsadecki, Margaret A. Johnson, Aimee M. Wilkin +6 more
2007AIDS Research and Human Retroviruses75 citations
Semantic Scholar
Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial.
J. Molina, K. Squires, P. Sax, P. Cahn +10 more
2019The Lancet HIV74 citations
Semantic Scholar
Genotypic correlates of susceptibility to HIV-1 attachment inhibitor BMS-626529, the active agent of the prodrug BMS-663068.
N. Zhou, B. Nowicka-Sans, Brian Mcauliffe, N. Ray +9 more
2014Journal of Antimicrobial Chemotherapy71 citations Open access
Semantic Scholar
Seven-Year Efficacy of a Lopinavir/Ritonavir-Based Regimen in Antiretroviral—Naïve HIV-1-Infected Patients
R. Murphy, B. D. da Silva, C. Hicks, J. Eron +6 more
2008HIV Clinical Trials70 citations Open access
Semantic Scholar
Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (TDF) Versus Efavirenz/Emtricitabine/TDF in Treatment-naive Adults With Human Immunodeficiency Virus Type 1 Infection: Week 96 Results of the Randomized, Double-blind, Phase 3 DRIVE-AHEAD Noninferiority Trial
C. Orkin, K. Squires, J. Molina, P. Sax +7 more
2020Clinical Infectious Diseases64 citations Open access
Semantic Scholar
Antiviral Activity, Pharmacokinetics, and Safety of BMS-488043, a Novel Oral Small-Molecule HIV-1 Attachment Inhibitor, in HIV-1-Infected Subjects
G. Hanna, J. Lalezari, J. Hellinger, D. Wohl +6 more
2010Antimicrobial Agents and Chemotherapy64 citations Open access
Semantic Scholar
Safety and efficacy of the HIV-1 attachment inhibitor prodrug BMS-663068 in treatment-experienced individuals: 24 week results of AI438011, a phase 2b, randomised controlled trial.
J. Lalezari, G. Latiff, C. Brinson, J. Echevarría +12 more
2015The Lancet HIV55 citations
Semantic Scholar
In Vivo Patterns of Resistance to the HIV Attachment Inhibitor BMS-488043
N. Zhou, B. Nowicka-Sans, Sharon Zhang, L. Fan +13 more
2010Antimicrobial Agents and Chemotherapy54 citations Open access
Semantic Scholar
Prediction of Virological Response and Assessment of Resistance Emergence to the HIV-1 Attachment Inhibitor BMS-626529 During 8-Day Monotherapy With Its Prodrug BMS-663068
N. Ray, C. Hwang, M. Healy, J. Whitcomb +4 more
2013Journal of Acquired Immune Deficiency Syndromes50 citations Open access
Semantic Scholar
Evidence of ongoing immune reconstitution in subjects with sustained viral suppression following 6 years of lopinavir-ritonavir treatment.
A. Landay, B. D. da Silva, M. King, M. Albrecht +12 more
2007Clinical Infectious Diseases49 citations
Semantic Scholar
Effects of Acid‐Reducing Agents on the Pharmacokinetics of Lopinavir/Ritonavir and Ritonavir‐Boosted Atazanavir
C. Klein, Y. Chiu, Yan Cai, K. Beck +6 more
2008Journal of clinical pharmacology46 citations
Semantic Scholar
Antiretroviral drug resistance in HIV-1
G. Hanna, R. D'Aquila
1999Current Infectious Disease Reports43 citations
Semantic Scholar
Viral Drug Resistance Through 48 Weeks, in a Phase 2b, Randomized, Controlled Trial of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir
M. Lataillade, N. Zhou, Samit R. Joshi, Sangil Lee +3 more
2017Journal of Acquired Immune Deficiency Syndromes42 citations Open access
Semantic Scholar
Predictive Genotypic Algorithm for Virologic Response to Lopinavir-Ritonavir in Protease Inhibitor-Experienced Patients
M. King, R. Rode, I. Cohen-Codar, V. Cálvez +3 more
2007Antimicrobial Agents and Chemotherapy42 citations Open access
Semantic Scholar
Drug-selected resistance mutations and non-B subtypes in antiretroviral-naive adults with established human immunodeficiency virus infection.
G. Hanna, Henri U. Balaguera, K. Freedberg, B. Werner +3 more
2003Journal of Infectious Diseases40 citations Open access
Semantic Scholar
Adherence to Chronic Hepatitis B Treatment Guideline Recommendations for Laboratory Monitoring of Patients Who Are Not Receiving Antiviral Treatment
T. Juday, Hong Tang, M. Harris, A. Powers +2 more
2010Journal of general internal medicine39 citations Open access
Semantic Scholar
Islatravir in combination with doravirine for treatment-naive adults with HIV-1 infection receiving initial treatment with islatravir, doravirine, and lamivudine: a phase 2b, randomised, double-blind, dose-ranging trial.
J. Molina, Y. Yazdanpanah, Alejandro Afani Saud, Christopher J Bettacchi +10 more
2021The Lancet HIV38 citations
Semantic Scholar
Comparison of Sequencing by Hybridization and Cycle Sequencing for Genotyping of Human Immunodeficiency Virus Type 1 Reverse Transcriptase
G. Hanna, V. Johnson, D. Kuritzkes, D. Richman +4 more
2000Journal of Clinical Microbiology38 citations Open access
Semantic Scholar
Efficacy and safety of elbasvir/grazoprevir in participants with hepatitis C virus genotype 1, 4, or 6 infection from the Asia–Pacific region and Russia: Final results from the randomized C‐CORAL study
Lai Wei, Ji-Dong Jia, Fu-Sheng Wang, Jun-Qi Niu +20 more
2018Journal of Gastroenterology and Hepatology29 citations Open access
Semantic Scholar
In Vitro Selection and Characterization of Human Immunodeficiency Virus Type 2 with Decreased Susceptibility to Lopinavir
Sherie V. Masse, Xiao-Zhi Lu, T. Dekhtyar, Liangjun Lu +7 more
2007Antimicrobial Agents and Chemotherapy29 citations Open access
Semantic Scholar
Safety and Efficacy of the HIV-1 Attachment Inhibitor Prodrug Fostemsavir in Antiretroviral-Experienced Subjects: Week 48 Analysis of AI438011, a Phase IIb, Randomized Controlled Trial
M. Thompson, J. Lalezari, R. Kaplan, Y. Pinedo +6 more
2017Antiviral Therapy26 citations
Semantic Scholar
Pharmacokinetic Interactions between BMS-626529, the Active Moiety of the HIV-1 Attachment Inhibitor Prodrug BMS-663068, and Ritonavir or Ritonavir-Boosted Atazanavir in Healthy Subjects
Li Zhu, M. Hruska, C. Hwang, V. Shah +4 more
2015Antimicrobial Agents and Chemotherapy25 citations Open access
Semantic Scholar
Brief Report: Efficacy and Safety of Oral Islatravir Once Daily in Combination With Doravirine Through 96 Weeks for Treatment-Naive Adults With HIV-1 Infection Receiving Initial Treatment With Islatravir, Doravirine, and Lamivudine
J. Molina, Y. Yazdanpanah, Alejandro Afani Saud, Christopher J Bettacchi +9 more
2021Journal of Acquired Immune Deficiency Syndromes22 citations Open access
Semantic Scholar
In Vitro Cross-Resistance Profile of Nucleoside Reverse Transcriptase Inhibitor (NRTI) BMS-986001 against Known NRTI Resistance Mutations
Zhu-Fang Li, B. Terry, W. Olds, Tricia L. Protack +9 more
2013Antimicrobial Agents and Chemotherapy22 citations Open access
Semantic Scholar
Raltegravir 1200 mg Once Daily vs 400 mg Twice Daily, With Emtricitabine and Tenofovir Disoproxil Fumarate, for Previously Untreated HIV-1 Infection: Week 96 Results From ONCEMRK, a Randomized, Double-Blind, Noninferiority Trial
P. Cahn, P. Sax, K. Squires, J. Molina +11 more
2018Journal of Acquired Immune Deficiency Syndromes20 citations Open access
Semantic Scholar
Human immunodeficiency virus type 1 hypersusceptibility to amprenavir in vitro can be associated with virus load response to treatment in vivo.
K. Zachary, G. Hanna, R. T. D'Aquila
2001Clinical Infectious Diseases20 citations Open access
Semantic Scholar
Efficacy and Safety of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) in Treatment-Naive Adults With HIV-1 and Transmitted Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations
A. Wong, D. Goldstein, J. Mallolas, E. Dejesus +12 more
2019Journal of Acquired Immune Deficiency Syndromes19 citations Open access
Semantic Scholar
Exploratory study comparing the metabolic toxicities of a lopinavir/ritonavir plus saquinavir dual protease inhibitor regimen versus a lopinavir/ritonavir plus zidovudine/lamivudine nucleoside regimen.
D. W. Cameron, S. Becker, M. King, B. D. da Silva +6 more
2007Journal of Antimicrobial Chemotherapy19 citations Open access
Semantic Scholar
Efficacy and safety of elbasvir/grazoprevir for 8 or 12 weeks for hepatitis C virus genotype 4 infection: A randomized study
T. Asselah, S. Pol, C. Hézode, V. Loustaud-Ratti +20 more
2019Liver international (Print)18 citations
Semantic Scholar
Model-Based Phase 3 Dose Selection for HIV-1 Attachment Inhibitor Prodrug BMS-663068 in HIV-1-Infected Patients: Population Pharmacokinetics/Pharmacodynamics of the Active Moiety, BMS-626529
Ishani Landry, Li Zhu, Malaz Abu Tarif, M. Hruska +7 more
2016Antimicrobial Agents and Chemotherapy18 citations Open access
Semantic Scholar
Randomized Placebo-Controlled Study of the Safety, Tolerability, Antiviral Activity, and Pharmacokinetics of 10-Day Monotherapy With BMS-986001, a Novel HIV NRTI, in Treatment-Experienced HIV-1–Infected Subjects
L. Cotte, P. Dellamonica, F. Raffi, Y. Yazdanpanah +10 more
2013Journal of Acquired Immune Deficiency Syndromes15 citations Open access
Semantic Scholar
Evaluation of Neural Tube Defects (NTDs) After Exposure to Raltegravir During Pregnancy
H. Shamsuddin, Casey L. Raudenbush, Brittany L. Sciba, Yun-Ping Zhou +5 more
2019Journal of Acquired Immune Deficiency Syndromes14 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

C. Hwang×13
Invite
C. Hwang — researcher profile on SciRah
J. Molina×12
Invite
J. Molina — researcher profile on SciRah
M. King×9
Invite
M. King — researcher profile on SciRah
M. Lataillade×9
Invite
M. Lataillade — researcher profile on SciRah

×9

Invite

M. Krystal — researcher profile on SciRah

Invite

S. Brun — researcher profile on SciRah

Invite

R. D'Aquila — researcher profile on SciRah

Sushma Kumar×6

Invite

Sushma Kumar — researcher profile on SciRah

Invite

P. Sklar — researcher profile on SciRah

Invite

K. Squires — researcher profile on SciRah

Invite

P. Sax — researcher profile on SciRah

T. Podsadecki×5

Invite

T. Podsadecki — researcher profile on SciRah